• Lithium orotate

Lithium orotate pure powder


The renewed interest is largely due to its alleged ability to achieve higher serum and brain lithium ion (Li+) concentrations than those observed with equivalent doses of lithium carbonate, which was first reported in 1978.

SKU: lithium-orotate-powder

ACTIVE INGREDIENT: lithium orotate


OTHER NAMES: 4-Pyrimidinecarboxylicacid, 1,2,3,6-tetrahydro-2,6-dioxo-, monolithium salt (9CI);Orotic acid,monolithium salt (8CI);4-Pyrimidinecarboxylicacid, 1,2,3,6-tetrahydro-2,6-dioxo-, lithium salt (1:1);

CAS NUMBER: 5266-20-6



MOLAR MASS: 162.03 g·mol−1

ITEM TYPE: powder

QUANTITY PER PACK: 1 to 2 grams



STORAGE: Store in a cool and dry place. Keep away from direct sunlight and heat.

WARNING: Keep out of reach of children. Do not take this or any other supplement if under the age of 18, pregnant or nursing a baby, or if you have any known or suspected medical conditions, and/or taking prescription drugs or over the counter medications.

DISCLAIMER: Always consult with a qualified health physician before taking any new dietary supplement. This product is not intended to diagnose, treat, cure, or prevent any diseases.

A micro spoon is added to Lithium orotate (yellow) = 4/18 mg (approximately).

The product is not intended for human use. For laboratory use only.


Over-the-counter lithium orotate is promoted as a health supplement for use as a low-dose source of lithium; however, very limited clinical evidence exists to support use. Noncontrolled studies have examined the use of low-dose lithium orotate in the treatment of alcoholism, migraines, and depression associated with bipolar disorder.


Adequate clinical studies are lacking to support dosage recommendations.


Avoid use in patients with significant renal disease.


Avoid use. Information regarding use of the orotate salt form of lithium in pregnancy and lactation is lacking. Adverse effects have been observed with use of lithium carbonate or citrate. Lithium is excreted in breast milk; adverse events have been reported in breastfeeding infants.


None well documented.

Adverse Reactions

Adverse effects have not been reported for low doses; however, at higher doses, adverse effects associated with lithium pharmaceutical preparations (lithium carbonate, lithium citrate) should be expected.


Information is limited. Nephrotoxicity is associated with high doses and long-term consumption of lithium. Short-term use of lithium orotate at low doses may not be associated with these toxicity concerns.